376 related articles for article (PubMed ID: 23813697)
41. 5α-reductase type 3 enzyme in benign and malignant prostate.
Titus MA; Li Y; Kozyreva OG; Maher V; Godoy A; Smith GJ; Mohler JL
Prostate; 2014 Feb; 74(3):235-49. PubMed ID: 24150795
[TBL] [Abstract][Full Text] [Related]
42. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase.
Wright AS; Douglas RC; Thomas LN; Lazier CB; Rittmaster RS
Endocrinology; 1999 Oct; 140(10):4509-15. PubMed ID: 10499505
[TBL] [Abstract][Full Text] [Related]
43. 5alpha-reductase activity in the prostate.
Steers WD
Urology; 2001 Dec; 58(6 Suppl 1):17-24; discussion 24. PubMed ID: 11750244
[TBL] [Abstract][Full Text] [Related]
44. Immunolocalization of androgen receptor in the epididymis of rats with dihydrotestosterone deficiency.
Trybek G; Kolasa A; Marchlewicz M; Wenda-Rózewicka L; Wiszniewska B
Reprod Biol; 2005 Nov; 5(3):291-301. PubMed ID: 16372046
[TBL] [Abstract][Full Text] [Related]
45. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
Stanczyk FZ; Azen CG; Pike MC
J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436
[TBL] [Abstract][Full Text] [Related]
46. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone.
Mohler JL; Titus MA; Wilson EM
Clin Cancer Res; 2011 Sep; 17(18):5844-9. PubMed ID: 21705451
[TBL] [Abstract][Full Text] [Related]
47. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R
Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955
[TBL] [Abstract][Full Text] [Related]
48. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
[TBL] [Abstract][Full Text] [Related]
49. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity.
Imperato-McGinley J; Gautier T; Cai LQ; Yee B; Epstein J; Pochi P
J Clin Endocrinol Metab; 1993 Feb; 76(2):524-8. PubMed ID: 8381804
[TBL] [Abstract][Full Text] [Related]
50. The antiandrogenic effect of finasteride against a mutant androgen receptor.
Wu Y; Chhipa RR; Zhang H; Ip C
Cancer Biol Ther; 2011 May; 11(10):902-9. PubMed ID: 21386657
[TBL] [Abstract][Full Text] [Related]
51. Do 5α-Reductase Inhibitors Raise Circulating Serum Testosterone Levels? A Comprehensive Review and Meta-Analysis to Explaining Paradoxical Results.
Traish AM; Krakowsky Y; Doros G; Morgentaler A
Sex Med Rev; 2019 Jan; 7(1):95-114. PubMed ID: 30098986
[TBL] [Abstract][Full Text] [Related]
52. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S
Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461
[TBL] [Abstract][Full Text] [Related]
53. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
54. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition.
Rhodes L; Primka RL; Berman C; Vergult G; Gabriel M; Pierre-Malice M; Gibelin B
Prostate; 1993; 22(1):43-51. PubMed ID: 8381228
[TBL] [Abstract][Full Text] [Related]
55. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
[TBL] [Abstract][Full Text] [Related]
56. Effects of the anti-androgen finasteride on 5alpha-reductase activity in human gingival fibroblasts in response to minocycline.
Soory M; Virdi H
J Clin Periodontol; 1998 Jan; 25(1):67-73. PubMed ID: 9477022
[TBL] [Abstract][Full Text] [Related]
57. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.
Mohler JL; Titus MA; Bai S; Kennerley BJ; Lih FB; Tomer KB; Wilson EM
Cancer Res; 2011 Feb; 71(4):1486-96. PubMed ID: 21303972
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of 5 alpha-reductase, receptor binding, and nuclear uptake of androgens in the prostate by a 4-methyl-4-aza-steroid.
Liang T; Heiss CE
J Biol Chem; 1981 Aug; 256(15):7998-8005. PubMed ID: 7263637
[TBL] [Abstract][Full Text] [Related]
59. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
Andriole GL; Humphrey P; Ray P; Gleave ME; Trachtenberg J; Thomas LN; Lazier CB; Rittmaster RS
J Urol; 2004 Sep; 172(3):915-9. PubMed ID: 15310997
[TBL] [Abstract][Full Text] [Related]
60. Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.
Makridakis N; Reichardt JK
J Mol Endocrinol; 2005 Jun; 34(3):617-23. PubMed ID: 15956333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
